Zabofloxacin D-aspartate

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H125016

CAS#: 1808295-63-7 (D-aspartate)

Description: Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia.

Chemical Structure

img
Zabofloxacin D-aspartate
CAS# 1808295-63-7 (D-aspartate)
Instruction

Theoretical Analysis

Hodoodo Cat#: H125016
Name: Zabofloxacin D-aspartate
CAS#: 1808295-63-7 (D-aspartate)
Chemical Formula: C23H27FN6O8
Exact Mass: 534.19
Molecular Weight: 534.500
Elemental Analysis: C, 51.68; H, 5.09; F, 3.55; N, 15.72; O, 23.95

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 219680-11-2(free base)   623574-00-5(HCl)   1808295-63-7 (D-aspartate)  

Synonym: Zabofloxacin D-aspartate; A0QFV40KA8; UNII-A0QFV40KA8; 1808295-63-7

IUPAC/Chemical Name: D-aspartic acid--(Z)-1-cyclopropyl-6-fluoro-7-(8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (1/1)

InChi Key: OBWXDHHUYKIHDV-USSIZITKSA-N

InChi Code: InChI=1S/C19H20FN5O4.C4H7NO4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17;5-2(4(8)9)1-3(6)7/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28);2H,1,5H2,(H,6,7)(H,8,9)/b23-14+;/t;2-/m.1/s1

SMILES Code: N[C@H](CC(O)=O)C(O)=O.CO\N=C1/CN(CC12CNC2)C3=C(F)C=C4C(=O)C(=CN(C5CC5)C4=N3)C(O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 534.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kocsis B, Gulyás D, Szabó D. Delafloxacin, Finafloxacin, and Zabofloxacin:
Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics (Basel). 2021 Dec
8;10(12):1506. doi: 10.3390/antibiotics10121506. PMID: 34943718; PMCID:
PMC8698389.

2: Kocsis B, Szabo D. Zabofloxacin for chronic bronchitis. Drugs Today (Barc).
2016 Sep;52(9):495-500. doi: 10.1358/dot.2016.52.9.2530595. PMID: 27883116.

3: Park HS, Oh SH, Kim HS, Choi DR, Kwak JH. Antimicrobial Activity of
Zabofloxacin against Clinically Isolated Streptococcus pneumoniae. Molecules.
2016 Nov 17;21(11):1562. doi: 10.3390/molecules21111562. PMID: 27869677; PMCID:
PMC6273590.

4: Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of
novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin,
zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May
23;15(1):34. doi: 10.1186/s12941-016-0150-4. PMID: 27215369; PMCID: PMC4878067.

5: Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, Lee JH, Park MJ, Yoo
KH, Oh YM. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation:
a multicenter, double-blind, double-dummy, randomized, controlled, Phase III,
non-inferiority trial. Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2265-75.
doi: 10.2147/COPD.S90948. PMID: 26543359; PMCID: PMC4622522.

6: Jin HE, Lee KR, Kang IH, Chung SJ, Shim CK. Determination of zabofloxacin in
rat plasma by liquid chromatography with mass spectrometry and its application
to pharmacokinetic study. J Pharm Biomed Anal. 2011 Mar 25;54(4):873-7. doi:
10.1016/j.jpba.2010.11.001. Epub 2010 Nov 9. PMID: 21112170.

7: Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA. Zabofloxacin (DW-224a)
activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Diagn Microbiol Infect Dis. 2008 Sep;62(1):110-2. doi:
10.1016/j.diagmicrobio.2008.05.010. Epub 2008 Jul 11. PMID: 18620833.